An algorithm for classifying tumors based on genomic aberrations and selecting representative tumor models

BMC Medical Genomics

Volumn 3, Issue , 2010, Pages

  Lu, Xin ^a   Zhang, Ke ^b   Van Sant, Charles ^c   Coon, John ^d   Semizarov, Dimitri ^a  

^a ABBOTT LABORATORIES   (United States)

^b UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c Astellas Pharmaceutical Inc   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER CELL CULTURE; CANCER CLASSIFICATION; CANCER RECURRENCE; CLASSIFICATION ALGORITHM; CLUSTER ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE CLUSTER; GENE DOSAGE; GENETIC ASSOCIATION; GENOMIC NON NEGATIVE MATRIX FACTORIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INSTRUMENT VALIDATION; LUNG NON SMALL CELL CANCER; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY CONTROL; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR MODEL; ALGORITHM; BIOLOGICAL MODEL; CELL LINE; CHROMOSOME ABERRATION; CLASSIFICATION; COLORECTAL TUMOR; COPY NUMBER VARIATION; GENE FREQUENCY; GENETICS; LUNG TUMOR; NEOPLASM;

ALGORITHMS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE; CHROMOSOME ABERRATIONS; CLUSTER ANALYSIS; COLORECTAL NEOPLASMS; DNA COPY NUMBER VARIATIONS; GENE FREQUENCY; HUMANS; LUNG NEOPLASMS; MELANOMA; MODELS, BIOLOGICAL; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 77953665612     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-3-23     Document Type: Article

References (35)

1. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. CL Vogel MA Cobleigh D Tripathy JC Gutheil LN Harris L Fehrenbacher DJ Slamon M Murphy WF Novotny M Burchmore, et al. J Clin Oncol 2002 20 3 719 726 10.1200/JCO.20.3.719 11821453
2. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. B Fisher J Dignam N Wolmark A DeCillis B Emir DL Wickerham J Bryant NV Dimitrov N Abramson JN Atkins, et al. J Natl Cancer Inst 1997 89 22 1673 1682 10.1093/jnci/89.22.1673 9390536
3. A 2009 update on the treatment of patients with hormone receptor-positive breast cancer. SJ Cleator E Ahamed RC Coombes C Palmieri, Clin Breast Cancer 2009 9 Suppl 1 6 S17 10.3816/CBC.2009.s.001 19561006
4. Personalized medicine and inhibition of EGFR signaling in lung cancer. AF Gazdar, N Engl J Med 2009 361 10 1018 1020 10.1056/NEJMe0905763 19692681
5. Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non-Small-Cell Lung Cancer 10.1093/jnci/dji112. F Cappuzzo FR Hirsch E Rossi S Bartolini GL Ceresoli L Bemis J Haney S Witta K Danenberg I Domenichini, et al. J Natl Cancer Inst 2005 97 9 643 655 10.1093/jnci/dji112 15870435
6. Mutations and response to epidermal growth factor receptor inhibitors. P Laurent-Puig A Lievre H Blons, Clin Cancer Res 2009 15 4 1133 1139 10.1158/1078-0432.CCR-08-0905 19228718
7. Monoclonal antibodies as therapeutic agents for cancer. M Harris, Lancet Oncol 2004 5 5 292 302 10.1016/S1470-2045(04)01467-6 15120666
8. Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non-Small-Cell Lung Cancer 10.1200/JCO.2005.01.0793. T Takano Y Ohe H Sakamoto K Tsuta Y Matsuno U Tateishi S Yamamoto H Nokihara N Yamamoto I Sekine, et al. J Clin Oncol 2005 23 28 6829 6837 10.1200/JCO.2005.01.0793 15998907
9. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. DJ Slamon GM Clark SG Wong WJ Levin A Ullrich WL McGuire, Science 1987 235 4785 177 182 10.1126/science.3798106 3798106
10. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. DJ Slamon B Leyland-Jones S Shak H Fuchs V Paton A Bajamonde T Fleming W Eiermann J Wolter M Pegram, et al. N Engl J Med 2001 344 11 783 792 10.1056/NEJM200103153441101 11248153
11. Translating insights from the cancer genome into clinical practice. L Chin JW Gray, Nature 2008 452 7187 553 563 10.1038/nature06914 18385729
12. The hallmarks of cancer. D Hanahan RA Weinberg, Cell 2000 100 1 57 70 10.1016/S0092-8674(00)81683-9 10647931
13. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. MA Shipp KN Ross P Tamayo AP Weng JL Kutok RC Aguiar M Gaasenbeek M Angelo M Reich GS Pinkus, et al. Nat Med 2002 8 1 68 74 10.1038/nm0102-68 11786909
14. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. TR Golub DK Slonim P Tamayo C Huard M Gaasenbeek JP Mesirov H Coller ML Loh JR Downing MA Caligiuri, et al. Science 1999 286 5439 531 537 10.1126/science.286.5439.531 10521349
15. Gene expression profiling predicts clinical outcome of breast cancer. LJ van 't Veer H Dai MJ van de Vijver YD He AA Hart M Mao HL Peterse K van der Kooy MJ Marton AT Witteveen, et al. Nature 2002 415 6871 530 536 10.1038/415530a 11823860
16. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. AA Alizadeh MB Eisen RE Davis C Ma IS Lossos A Rosenwald JC Boldrick H Sabet T Tran X Yu, et al. Nature 2000 403 6769 503 511 10.1038/35000501 10676951
17. Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. EA Maher C Brennan PY Wen L Durso KL Ligon A Richardson D Khatry B Feng R Sinha DN Louis, et al. Cancer Res 2006 66 23 11502 11513 10.1158/0008-5472.CAN-06-2072 17114236
18. DNA copy number amplification profiling of human neoplasms. S Myllykangas J Himberg T Bohling B Nagy J Hollmen S Knuutila, Oncogene 2006 25 55 7324 7332 10.1038/sj.onc.1209717 16751803
19. Classification of human cancers based on DNA copy number amplification modeling. S Myllykangas J Tikka T Bohling S Knuutila J Hollmen, BMC Med Genomics 2008 1 15 10.1186/1755-8794-1-15 18477412
20. Genomic imbalances in 5918 malignant epithelial tumors: an explorative meta-analysis of chromosomal CGH data. M Baudis, BMC Cancer 2007 7 226 10.1186/1471-2407-7-226 18088415
21. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. J Lapointe C Li CP Giacomini K Salari S Huang P Wang M Ferrari T Hernandez-Boussard JD Brooks JR Pollack, Cancer Res 2007 67 18 8504 8510 10.1158/0008-5472.CAN-07-0673 17875689
22. Cross-platform array comparative genomic hybridization meta-analysis separates hematopoietic and mesenchymal from epithelial tumors. K Jong E Marchiori A van der Vaart SF Chin B Carvalho M Tijssen PP Eijk P van den Ijssel H Grabsch P Quirke, et al. Oncogene 2007 26 10 1499 1506 10.1038/sj.onc.1209919 16936777
23. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. DR Carrasco G Tonon Y Huang Y Zhang R Sinha B Feng JP Stewart F Zhan D Khatry M Protopopova, et al. Cancer Cell 2006 9 4 313 325 10.1016/j.ccr.2006.03.019 16616336
24. Learning the parts of objects by non-negative matrix factorization. DD Lee HS Seung, Nature 1999 401 6755 788 791 10.1038/44565 10548103
25. Algorithms for Non-negative Matrix Factorization. DD Lee HS Seung, Advances In Neural Information Processing Systems 2001 14 556 562
26. Metagenes and molecular pattern discovery using matrix factorization. JP Brunet P Tamayo TR Golub JP Mesirov, Proc Natl Acad Sci USA 2004 101 12 4164 4169 10.1073/pnas.0308531101 15016911
27. Random Forests. L Breiman, Machine Learning 2001 45 1 5 32 10.1023/A:1010933404324 (Pubitemid 32933532)
28. Positive matrix factorization: A non-negative factor model with optimal utilization of error estimates of data values. P Paatero U Tapper, Environmetrics 1994 5 2 111 126 10.1002/env.3170050203
29. The comparison of dendrograms by objective methods. RR Sokal FJ Rohlf, Taxon 1962 11 33 40 10.2307/1217208
30. Estimating the dimension of a model. G Schwarz, Annals of Statistics 1978 6 2 461 464 10.1214/aos/1176344136
31. Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas. G Hodgson JH Hager S Volik S Hariono M Wernick D Moore N Nowak DG Albertson D Pinkel C Collins, et al. Nat Genet 2001 29 4 459 464 10.1038/ng771 11694878
32. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. X Zhao BA Weir T LaFramboise M Lin R Beroukhim L Garraway J Beheshti JC Lee K Naoki WG Richards, et al. Cancer Res 2005 65 13 5561 5570 10.1158/0008-5472.CAN-04-4603 15994928
33. A K-means clustering algorithm. JA Hartigan MA Wong, Applied Statistics 1979 28 100 108 10.2307/2346830
34. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Q Wang S Diskin E Rappaport E Attiyeh Y Mosse D Shue E Seiser J Jagannathan S Shusterman M Bansal, et al. Cancer Res 2006 66 12 6050 6062 10.1158/0008-5472.CAN-05-4618 16778177
35. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group. J Schneiderman WB London GM Brodeur RP Castleberry AT Look SL Cohn, J Clin Oncol 2008 26 6 913 918 10.1200/JCO.2007.13.9493 18281664